文献速递脑血管病外科神经重症

降胆固醇药物用于治疗动脉瘤性蛛网膜下腔出血:随机对照试验的系统综述与Meta分析

Cholesterol-Reducing Agents for Treatment of Aneurysmal Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · World Neurosurg · 2017-02-10

该系统综述与Meta分析检索截至2016年9月的文献,纳入10项随机对照试验共1214例动脉瘤性蛛网膜下腔出血患者,其中587例接受他汀类药物、627例为安慰剂组。他汀类药物显著降低脑血管痉挛(OR 0.46,95%CI 0.28-0.78,P=0.002)和迟发性缺血性神经功能缺损(OR 0.72,95%CI 0.54-0.97,P=0.03),但死亡率(OR 0.77,95%CI 0.54-1.11,P=0.16)和神经功能预后不良(OR 0.96,95%CI 0.75-1.23,P=0.74)无显著下降。

要点

  • 他汀类药物显著降低脑血管痉挛(OR 0.46,95%CI 0.28-0.78,P=0.002)。
  • 他汀类药物显著降低迟发性缺血性神经功能缺损(OR 0.72,95%CI 0.54-0.97,P=0.03)。
  • 死亡率与神经功能预后不良无显著下降,作者呼吁进一步研究。

核心结论

  • Meta分析显示,动脉瘤性蛛网膜下腔出血患者使用他汀类药物可能具有降低脑血管痉挛和迟发性缺血性神经功能缺损发生的潜力,但在降低死亡率和神经功能预后不良方面无获益。
  • 作者认为这呼唤进一步研究。

研究设计与样本

  • 系统综述与随机对照试验的Meta分析,检索Cochrane图书馆Cochrane对照试验中心注册库、Medline、Embase和Science Citation Index Expanded数据库,检索截至2016年9月。
  • 由3名独立作者提取数据并进行严格评价,根据异质性程度采用固定或随机效应模型计算合并结果。
  • 共纳入10项随机对照试验、1214例患者,其中587例接受他汀类药物,627例为安慰剂组。

主要发现

  • 他汀类药物显著降低脑血管痉挛(OR 0.46,95%CI 0.28-0.78,P=0.002)。
  • 他汀类药物显著降低迟发性缺血性神经功能缺损(OR 0.72,95%CI 0.54-0.97,P=0.03)。
  • 死亡率无显著下降(OR 0.77,95%CI 0.54-1.11,P=0.16)。
  • 神经功能预后不良无显著下降(OR 0.96,95%CI 0.75-1.23,P=0.74)。

局限性

  • 作者在结论中呼吁进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aneurysmal hemorrhage induced cerebral vasospasm; delayed ischemic neurologic deficit (DIND), poor neurologic outcome, and mortality are major causes of mortality and morbidity. The effects of cholesterol-lowering agents in these patients remain controversial. This up-to-date systematic review and meta-analysis aimed to evaluate the efficacy of statin use in patients with aneurysmal subarachnoid hemorrhage. METHODS: A systematic review of the literature conducted using electronic database searched up to September 2016 included Cochrane Central Register of Controlled Trials in the Cochrane Library, Medline, Embase, and Science Citation Index Expanded database to identify relevant studies. Data were extracted and critically appraised by 3 independent authors. In addition, fixed or random-effects model were applied to calculated pooled results based on degree of heterogeneity. RESULTS: Ten randomized controlled trials were identified with 1214 patients; 587 patients received statins and there were 627 patients in the placebo group. Statins were found to significantly reduce cerebral vasospasm (odds ratio [OR], 0.46; 95% confidence interval [CI], 0.28-0.78, P = 0.002) and DIND (OR, 0.72; 95% CI, 0.54-0.97; P = 0.03). However, there was no significant decrease in mortality (OR, 0.77; 95% CI, 0.54-1.11; P = 0.16) and poor neurologic outcome (OR, 0.96; 95% CI, 0.75-1.23; P = 0.74). CONCLUSIONS: The outcome of this meta-analysis showed that use of statins in aneurysmal subarachnoid hemorrhage might have the potential to decrease occurrence of vasospasm and DIND. However, there was no benefit in the reduction of mortality and poor neurologic outcome. This is a call for further research.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Akhigbe T, Zolnourian A, Bulters D, et al. Cholesterol-Reducing Agents for Treatment of Aneurysmal Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis of Randomized Controlled Trials. World Neurosurg. 2017. PMID: 28192263. doi:10.1016/j.wneu.2017.01.125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。